Misidentification of retinal stem cells
April 8th 2009Ciliary epithelial cells inside the eye, previously proposed as retinal cell stems, have now been established as being normal adult cells. The misidentification was uncovered by Michael Dyer, PhD and researchers at the St Jude Department of Developmental Neurobiology.
Eye diseases in pre-school children more common than first thought
April 8th 2009In what is believed to be the first comprehensive eye disease study among urban pre-schoolers, investigators writing in the April issue of the journal Ophthalmology report that while vision problems are rare, they are more common than once thought.
Are patients with diabetes more susceptible to open angle glaucoma?
April 1st 2009Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?
Prosthetic implants to oxygenate retinal tissue
April 1st 2009Blindness in millions of people with diseases that starve eye tissue and nerves of oxygen might be averted with a procedure being developed by researchers at Oak Ridge National Laboratory, the University of Southern California and the University of Tennessee.
Red meat consumption associated with early AMD
March 25th 2009According to Eye Research Australia researchers at the University of Melbourne, a high intake of fresh and processed red meat is positively associated with early AMD, the leading cause of blindness among older people. Diet has often been postulated to alter the risk of AMD.
New wet AMD treatment a step closer
March 25th 2009The CABERNET (CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy) clinical trial is pivotal to establishing the safety and effectiveness of a beta radiation based focal epimacular brachytherapy device. Its development in bringing a paradigm shift in the way retina specialists treat wet AMD patients moved a step closer as Neovista Inc. secured more than $18 million in its Series D private venture funding round.